Ask Warren

RollingStone

214610 · KOSDAQ · ₩214610 · 롤링스톤

₩2,290 ₩0 (0.00%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −42.32%
Market cap
₩19B
Enterprise value
₩19B
P/E
—
P/B
1.7×
Dividend yield
0.0%
ROE
−191.1%
Net margin
−30.6%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−51.3% from the high

₩2,255Today: ₩2,290 – ₩2,290₩4,705

Returns

  • 1W0.0%
  • 1M0.0%
  • 3M0.0%
  • 6M0.0%
  • YTD−36.5%
  • 1Y−42.3%
Volume today
—
Traded today
—
Listed shares
8,383,322
EPS (12 months)
−₩2,581
Earnings yield −112.7%
SellBuy
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

43Quiet
  • BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
  • MomentumFlat0% over the last month; the price is below its 20-day average.

Signals describe activity, not recommendations. Not financial advice.

RollingStone stock overview

RollingStone (롤링스톤, KRX: 214610) is listed on KOSDAQ, in the Medical & precision devices sector. , Ltd. Its shares closed at ₩2,290 on Oct 27, 2026, unchanged on the day, giving it a market value of ₩19B.

Key facts

Market cap
₩19B
Sector
Medical & precision devices
Latest price change
0.00%
As of
Oct 27, 2026
Main business
, Ltd.

Quick answers about RollingStone

What does RollingStone do?
, Ltd. was founded in 2009 and develops and sells molecular diagnostic instruments and kits based on its LabChip technology, with a focus on infectious disease testing. Its diagnostics segment spans molecular, biochemical and immunological tests, including a malaria molecular diagnostic kit, respiratory and food-safety tests, and point-of-care blood glucose, hemoglobin and cholesterol meters.
What is the market cap of RollingStone?
The market capitalisation of RollingStone was ₩19B at the close on Oct 27, 2026.
Who are the largest shareholders of RollingStone?
According to the latest official filings, the largest reported holders are J.B. Asset Management (38.56%, as of Apr 3, 2026); Kim Woo-chan (16.43%, as of Mar 11, 2026); J&Star Fund (14.09%, as of Jan 15, 2025).
When is the next earnings report from RollingStone?
Korean companies rarely announce results dates in advance. Based on when RollingStone filed the same report in past years, its next 3q results is expected around Nov 14, 2026.

Company profile

Rolling Stone Co., Ltd. was founded in 2009 and develops and sells molecular diagnostic instruments and kits based on its LabChip technology, with a focus on infectious disease testing. Its diagnostics segment spans molecular, biochemical and immunological tests, including a malaria molecular diagnostic kit, respiratory and food-safety tests, and point-of-care blood glucose, hemoglobin and cholesterol meters. The company is also developing digital healthcare and has a petroleum wholesale business that supplies fuel through refiners, distributors and gas stations.

Written by AI from the company's latest annual report.

Korean name
롤링스톤
Sector
Medical & precision devices
Themes
Medical devicesAI healthcare
CEO
이재성
Founded
Mar 2009
Listed
Oct 2020
Listed shares
8,383,322
Fiscal year ends
Month 12
Website
www.micobiomed.com

Similar companies

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: RollingStone / 롤링스톤 / 214610 / KRX:214610

Source: KRX statistical information